Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer

ECOG 5597

Daniel D. Karp, Sandra J. Lee, Steven M. Keller, Gail Shaw Wright, Seena Aisner, Steven Alan Belinsky, David H. Johnson, Michael R. Johnston, Gary Goodman, Gerald Clamon, Gordon Okawara, Randolph Marks, Eric Frechette, Worta McCaskill-Stevens, Scott M. Lippman, John Ruckdeschel, Fadlo R. Khuri

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200 <g versus placebo daily for 48 months. Participation was 6 to 36 months postoperatively and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, negative chest x-ray, and no other evidence of recurrence. Results The first interim analysis in October 2009, with 46% of the projected end points accumulated, showed a trend in favor of the placebo group with a low likelihood that the trial would become positive; thus, the study was stopped. One thousand seven hundred seventy-two participants were enrolled, with 1,561 patients randomly assigned. Analysis was updated in June 2011 with the maturation of 54% of the planned end points. Two hundred fifty-two SPTs (from 224 patients) developed, of which 98 (from 97 patients) were lung cancer (38.9%). Lung and overall SPT incidence were 1.62 and 3.54 per 100 person-years, respectively, for selenium versus 1.30 and 3.39 per 100 person-years, respectively, for placebo (P = .294). Five-year disease-free survival was 74.4% for selenium recipients versus 79.6% for placebo recipients. Grade 1 to 2 toxicity occurred in 31% of selenium recipients and 26% of placebo recipients, and grade ≥ 3 toxicity occurred in less than 2% of selenium recipients versus 3% of placebo recipients. Compliance was excellent. No increase in diabetes mellitus or skin cancer was detected. Conclusion Selenium was safe but conferred no benefit over placebo in the prevention of SPT in patients with resected NSCLC.

Original languageEnglish (US)
Pages (from-to)4179-4187
Number of pages9
JournalJournal of Clinical Oncology
Volume31
Issue number33
DOIs
StatePublished - Nov 20 2013

Fingerprint

Chemoprevention
Selenium
Non-Small Cell Lung Carcinoma
Placebos
Lung Neoplasms
Neoplasms
Incidence
Skin Neoplasms
Primary Prevention
Vitamins
Compliance
Disease-Free Survival
Diabetes Mellitus
Thorax
Yeasts
X-Rays
Biopsy
Recurrence
Lung
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer : ECOG 5597. / Karp, Daniel D.; Lee, Sandra J.; Keller, Steven M.; Wright, Gail Shaw; Aisner, Seena; Belinsky, Steven Alan; Johnson, David H.; Johnston, Michael R.; Goodman, Gary; Clamon, Gerald; Okawara, Gordon; Marks, Randolph; Frechette, Eric; McCaskill-Stevens, Worta; Lippman, Scott M.; Ruckdeschel, John; Khuri, Fadlo R.

In: Journal of Clinical Oncology, Vol. 31, No. 33, 20.11.2013, p. 4179-4187.

Research output: Contribution to journalArticle

Karp, DD, Lee, SJ, Keller, SM, Wright, GS, Aisner, S, Belinsky, SA, Johnson, DH, Johnston, MR, Goodman, G, Clamon, G, Okawara, G, Marks, R, Frechette, E, McCaskill-Stevens, W, Lippman, SM, Ruckdeschel, J & Khuri, FR 2013, 'Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597', Journal of Clinical Oncology, vol. 31, no. 33, pp. 4179-4187. https://doi.org/10.1200/JCO.2013.49.2173
Karp, Daniel D. ; Lee, Sandra J. ; Keller, Steven M. ; Wright, Gail Shaw ; Aisner, Seena ; Belinsky, Steven Alan ; Johnson, David H. ; Johnston, Michael R. ; Goodman, Gary ; Clamon, Gerald ; Okawara, Gordon ; Marks, Randolph ; Frechette, Eric ; McCaskill-Stevens, Worta ; Lippman, Scott M. ; Ruckdeschel, John ; Khuri, Fadlo R. / Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer : ECOG 5597. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 33. pp. 4179-4187.
@article{958f835fd3ef411fae19d24e4576cab8,
title = "Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597",
abstract = "Purpose Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200",
author = "Karp, {Daniel D.} and Lee, {Sandra J.} and Keller, {Steven M.} and Wright, {Gail Shaw} and Seena Aisner and Belinsky, {Steven Alan} and Johnson, {David H.} and Johnston, {Michael R.} and Gary Goodman and Gerald Clamon and Gordon Okawara and Randolph Marks and Eric Frechette and Worta McCaskill-Stevens and Lippman, {Scott M.} and John Ruckdeschel and Khuri, {Fadlo R.}",
year = "2013",
month = "11",
day = "20",
doi = "10.1200/JCO.2013.49.2173",
language = "English (US)",
volume = "31",
pages = "4179--4187",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer

T2 - ECOG 5597

AU - Karp, Daniel D.

AU - Lee, Sandra J.

AU - Keller, Steven M.

AU - Wright, Gail Shaw

AU - Aisner, Seena

AU - Belinsky, Steven Alan

AU - Johnson, David H.

AU - Johnston, Michael R.

AU - Goodman, Gary

AU - Clamon, Gerald

AU - Okawara, Gordon

AU - Marks, Randolph

AU - Frechette, Eric

AU - McCaskill-Stevens, Worta

AU - Lippman, Scott M.

AU - Ruckdeschel, John

AU - Khuri, Fadlo R.

PY - 2013/11/20

Y1 - 2013/11/20

N2 - Purpose Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200

AB - Purpose Selenium has been reported to have chemopreventive benefits in lung cancer. We conducted a double-blind, placebo-controlled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected non-small-cell lung cancer (NSCLC) receiving selenium supplementation. Patients and Methods Patients with completely resected stage I NSCLC were randomly assigned to take selenized yeast 200

UR - http://www.scopus.com/inward/record.url?scp=84892947736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892947736&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.49.2173

DO - 10.1200/JCO.2013.49.2173

M3 - Article

VL - 31

SP - 4179

EP - 4187

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -